Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Nov;19(4):e24.
doi: 10.1136/eb-2016-102474. Epub 2016 Sep 9.

Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram

Affiliations
Comment

Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram

Nathan Herrmann. Evid Based Ment Health. 2016 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: NH has received consultation fees from Astellas, Merck and Lilly.

Comment on

References

    1. Gallagher D, Herrmann N. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care. Neurodgener Dis Manag 2015;51:77–83. - PubMed
    1. Reus VI, Fochtmann LJ, Eyler AE, et al. . The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016;173:543–6. 10.1176/appi.ajp.2015.173501 - DOI - PubMed
    1. Porsteinsson AP, Drye LT, Pollock BG, et al. . Effects of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311: 682–91. 10.1001/jama.2014.93 - DOI - PMC - PubMed
    1. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antispychotics and antidepressants: a comprehensive review. CNS Drugs 2014;28:887–920. 10.1007/s40263-014-0196-9 - DOI - PubMed

LinkOut - more resources